Intismeran autogene has delivered the first positive phase 3 for an individualised neoantigen therapy, while autogene cevumeran's colorectal trial was…
irAEs often track with response to checkpoint inhibitors, but immortal time bias inflates the link. Here is what the evidence…
Beyond T cell engagers: how receptor-targeting and PD-1 x VEGF bispecific antibodies are selected, what their toxicity looks like, and…
Claudin 18.2 has a 75% companion diagnostic cut-off for zolbetuximab while its lead ADC succeeded at 25%, and B7-H3 ADCs…
Whole slide imaging is cleared for primary diagnosis, but quantitative biomarker scoring is a different validation problem. Here is where…
Most AI biomarker models never reach a patient, and the gap is usually evidence rather than algorithms. Here is the…
Enrichment, stratified, basket, umbrella and platform designs compared, with the trials that set the template and the screening, assay and…
ADC plus checkpoint inhibitor combinations are moving into first-line care, but target expression has not predicted benefit for TROP2 ADCs.…
How tumour-informed and tumour-agnostic MRD testing, early ctDNA molecular response and serial surveillance are reshaping checkpoint inhibitor trials, and what…
Tebentafusp and tarlatamab have shown T cell engagers can extend survival in solid tumours. Here is where targets, toxicity management…
300+ senior leaders. Two streams. One agenda: advancing precision oncology.